Market Update (NYSE:PFE): Help Pfizer Change The Future Of Healthy Aging

[Business Wire] – Pfizer Inc. is challenging people across the United States to develop the next big idea in healthy aging through a unique partnership with crowdfunding platform Indiegogo. As the first pharmaceutical company to partner with Indiegogo, Pfizer will tap into the 400,000-strong Pfizer Get Old community and Indiegogo’s vast pool of entrepreneurs to submit and vote on innovative products or services that … Read more on this. Pfizer Inc. (PFE) , valued at $209.57B, opened this morning at $34.68. During today’s session, PFE traded between $34.42 to $34.79 with a trailing 52-week range being $28.25 to $36.46. Priced at 14.26x this year’s forecasted earnings, PFE shares are relatively expensive compared to the industry’s -0.02x forward p/e ratio. And for income investors, the company pays shareholders $1.20 per share annually in dividends, yielding 3.40%. In a review of the consensus earnings estimate this quarter, 15 sell-side analysts are looking at $0.62 per share, which would be $0.06 better than the year-ago quarter and a $0.03 sequential increase. Investors should also note that the full-year EPS estimate of $2.44 is a $0.24 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $12.94 Billion. If realized, that would be a 9.20% increase over the year-ago quarter. In terms of ratings, Berenberg Initiated PFE at Hold (May 12, 2016). Previously, Sun Trust Rbsn Humphrey upgraded PFE from Reduce to Neutral. Given all the information above, we should disclose to readers that the average price target is $38.71, which is 11.62% above than it opened this morning. See more in (NYSE:PFE) Similar Articles: Market Update (NYSE:PFE): Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer